Biotechnology-focused domestic startup Massive Bio received an investment of $16.5 million under the leadership of Revo Capital

Massive Bio, a local startup that develops artificial intelligence-based technology solutions for oncology clinical trials, received an investment of $16.5 million under the leadership of Revo Capital.

Massive Bio, a local initiative that works to find the best treatment options for cancer patients, received an investment of $16.5 million in the Series B tour. Kenan Turnacioglu, IFC (World Bank), DEG-Deutsche Investitions-und Entwicklungsgesellschaft mbH, TFS Services, ImpactAssets and SiteGround Capital participated in the tour led by Revo Capital.

Founded in 2015 by Dr. Selin Kurnaz, Cagatay Culcuoglu, and Dr. Arturo Loaiza-Bonilla, Massive Bio is the only company that brings cancer patients together with clinical studies, no matter where they live in the world and under which economic conditions, and that brings together technology, big data and service within hours. When cancer patients enter their own information into the system, Massive Bio’s artificial intelligence algorithms match the patient’s data with the most appropriate treatment method and the nearest clinical research center.

We told you that the startup received an investment of $9 million last June. Together with the new investment, the total investment received by the venture was $23.3 million.

Massive Bio recently announced that it has added over 100,000 patients to its platform. The platform provides relevant clinical trials to cancer patients using artificial intelligence. It enables patients to find treatment options faster and enables life sciences companies to engage in broader, more inclusive, population-based recruitment instead of traditional facility-specific recruitment. Massive Bio’s AI technology can improve healthcare access and equity by automatically matching patient data with cancer trial data to improve the patient experience in ways they couldn’t before.

“Our mission is to create hope and empower cancer patients by helping them find the best treatment options that often require immediate access to trials,” said Selin Kurnaz, co-founder and CEO of Massive Bio. This is a tremendous time point when advanced technology intersects with medical science to change lives in a meaningful way. Joining our team of highly experienced experts will help us push the boundaries of our mission and continue to implement our strategic priorities as we enter 2023.”

Source: Egirisim / Translated by Irem Yildiz

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button